14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BOLD vs DERM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Journey Medical Corporation (DERM) on higher Unified Composite conviction (36.8/100 SELL vs. 40.9/100 SELL) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while DERM wins 4–2 across the 6-pillar growth and valuation breakdown. BOLD trades at $2.32 (N/M Forward P/E, 0.0% operating margin) versus DERM at $3.30 (8.3x Forward P/E, -2.9% operating margin).
Composite vs. Pillar Nuance: While DERM currently prints a higher short-term Unified Composite Score (40.9/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2.9% operating margin) and revenue trajectory (+0.0% vs. +7.6% YoY).
Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both BOLD (36.8/100 SELL) and DERM (40.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile DERM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs DERM. Trailing 12-month operating profitability (BOLD 0.0% vs DERM -2.9%) and valuation multiples (BOLD N/M vs DERM 8.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $100.2M market capitalization and -2.9% operating margin.
OpEx & R&D Reinvestment68.8% of Rev ($48M)
90D Engineering Disclosures0 Published
Investor FAQ BOLD vs DERM Key Questions & Quantitative Answers
As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Journey Medical Corporation (DERM) on higher Unified Composite conviction (36.8/100 SELL vs. 40.9/100 SELL) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while DERM wins 4–2 across the 6-pillar growth and valuation breakdown. BOLD trades at $2.32 (N/M Forward P/E, 0.0% operating margin) versus DERM at $3.30 (8.3x Forward P/E, -2.9% operating margin). Composite vs. Pillar Nuance: While DERM currently prints a higher short-term Unified Composite Score (40.9/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -2.9% operating margin) and revenue trajectory (+0.0% vs. +7.6% YoY). Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both BOLD (36.8/100 SELL) and DERM (40.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile DERM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DERM leads the Growth & Scale pillar: BOLD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DERM at +7.6% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (65.9% gross margin, -2.9% operating margin). On trailing 12-month operating scale, BOLD generates N/A in USD-normalized revenue versus $70M for DERM. In operating R&D and SG&A reinvestment, BOLD deploys N/A (0 90-day corporate R&D disclosures) versus 68.8% of Rev ($48M) (0 disclosures) for DERM.
DERM screens cheaper on headline valuation multiples. BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DERM trades at 8.3x Forward P/E, 17.6x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (-12.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BOLD (-64.6% ROE) versus DERM (-17.6% ROE) capital efficiency.
In options market volatility and institutional positioning, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk). By comparison, DERM carries 17.9% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.08β · 77% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.